← Leaderboards
Najah Abi Gerges
Anabios Corporation
$1,379,750
Attributed
$1,379,750
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2019–20$2M$1.5M$1M$500K$0
'19
'20
Funding mix
By agency
NIH$1,132,289 · 1
FDA$247,461 · 1
By mechanism
R44$1,132,289 · 1
U01$247,461 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Adverse Event”
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$26,732,375
- Barbara Halina Braffett · George Washington University$18,816,779
- Ionut Bebu · George Washington University$18,816,779
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
Research focus
Adverse EventAreaArrhythmiaAutomationBaseBiocompatible MaterialsBiomedical EngineeringB-LymphocytesBrightfield MicroscopyCardiacCardiac MyocytesCardiotoxicityCell AdhesionCellsCell SeparationChemotherapeutic AgentCollaborationsCost EffectiveCustomDangerousnessData AcquisitionData AnalysesDetectionAdult
Grant awards (2)
Development of an Integrated Platform for the Use of Adult Human Primary Cardiomyocytes in Preclinical Safety Assessment$1,132,289
R44 · FY2020 · TR · contact PI
DEVELOPMENT AND QUALIFICATION OF A BIOMARKER FOR PRECLINICALLY IDENTIFYING THE PRO-ARRHYTHMIA RISK OF DRUGS BASED ON CONTRACTILITY MEASUREMENTS CONDUCTED IN HUMAN ADULT PRIMARY CARDIOMYOCYTES$247,461
U01 · FY2019 · FD · contact PI